Volume replacement therapy in cardiac surgery: effect on renal function.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2011-003173-28-FI

Enrollment

850

Registered

2012-03-28

Start date

2012-06-13

Completion date

Unknown

Last updated

2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Trade Name: VOLUVEN 60MG/ML INF, LIUOS Product Name: VOLUVEN 60MG/ML Product Code: B05AA07 Pharmaceutical Form: Solution for infusion Trade Name: RINGER-ACETAT BAXTER VIAFLO INF, LIUOS Product Nam

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 750 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 250

Exclusion criteria

Exclusion criteria: - critical preoperative status - hematological malignity - hematological disease - end stage of kidney injury (GFR<20 mL/min) - aortic surgery with total arrest (reconstruction of ascendent aorta without total arrest will be included) - surgery with total arrest - transplantation.

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Secondary

Measure	Time frame
Secondary end point(s): - reoperation rate - blood products transfusion (red blood cells, octoplase, platelets) - perioperative fluid balance - ICU stay length - hospital stay length - allergic reactions - 28-days mortality - 1 year mortality	—

Countries

Finland

Outcome results